Silence Therapeutics
29 hedge funds and large institutions have $183M invested in Silence Therapeutics in 2022 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 9 increasing their positions, 5 reducing their positions, and 3 closing their positions.
747% more capital inflows, than outflows
Capital inflows: $97.9M | Capital outflows: $11.6M
133% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 3
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
80% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 5
17.35% more ownership
Funds ownership: 34.64% → 51.99% (+17%)
16% more funds holding
Funds holding: 25 → 29 (+4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Lombard Odier Asset Management (Europe)
London,
United Kingdom
|
+$33.9M |
| 2 |
TCG Crossover Management
Palo Alto,
California
|
+$22.2M |
| 3 |
ACM
Aquilo Capital Management
San Francisco,
California
|
+$13.3M |
| 4 |
Deep Track Capital
Greenwich,
Connecticut
|
+$10.5M |
| 5 |
BVF Inc
San Francisco,
California
|
+$8.86M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Consonance Capital Management
New York
|
-$7.52M |
| 2 |
Great Point Partners
Greenwich,
Connecticut
|
-$3.5M |
| 3 |
Bellevue Group
Kuesnacht,
Switzerland
|
-$361K |
| 4 |
William Blair & Company
Chicago,
Illinois
|
-$97.7K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$36.2K |
SLN Hedge Fund Activity: Q3 2022 in Review
29 of the 5,832 institutional investors tracked by Wall St. Rank reported a position in Silence Therapeutics (SLN) for Q3 2022, worth a combined $183M — up 58% from $116M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new SLN positions and 3 closed out — a net gain of 4 holders — while 9 added to existing stakes and 5 trimmed.
The largest buyer was Lombard Odier Asset Management (Europe), opening a new position worth an estimated $33.9M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $7.52M sold.
- 29 institutional investors held Silence Therapeutics (SLN) as of Q3 2022, up from 25 in Q2 2022.
- Funds reported $183M of Silence Therapeutics stock for Q3 2022, up 58% quarter-over-quarter.
- 7 funds opened new Silence Therapeutics positions in Q3 2022 and 3 closed out, a net change of +4 holders.
- The largest Silence Therapeutics buyer in Q3 2022 was Lombard Odier Asset Management (Europe), an estimated $33.9M added.
- The largest Silence Therapeutics seller in Q3 2022 was Consonance Capital Management, an estimated $7.52M sold.
Based on aggregated 13F filings for Q3 2022.